FTC Releases Second Interim Staff Report on Prescription Drug …
3 days ago · The FTC’s latest interim staff report is part of the Commission’s ongoing study of the PBM industry. This report highlights several key insights gained from data and documents obtained from special orders the FTC issued in 2022 under Section 6(b) of the FTC Act, as well as from publicly available information:
FTC Releases Interim Staff Report on Prescription Drug Middlemen
The interim staff report, which is part of an ongoing inquiry launched in 2022 by the FTC, details how increasing vertical integration and concentration has enabled the six largest PBMs to manage nearly 95 percent of all prescriptions filled in the United States.
3 days ago · The FTC issues this staffreport in connection with our ongoing study of the PBM industry. In June 2022, the FTC issued special orders pursuant to Section 6(b) of the Federal Trade Commission Act to the six largest PBMs (the “PBM respondents” or “respondents”), including . the Big 3 PBMs (the “6(b) Orders”). 24
PBMs made billions marking up specialty drugs by more than …
2 days ago · The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through ...
FTC alleges PBMs cost consumers $7.3 billion marking up drug …
3 days ago · The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...
FTC doubles down on PBM criticism in new report
2 days ago · The FTC's first report drew a strong response from the PBM sector, with lawsuits filed in both directions. The FTC has accused the big three of operating a "perverse drug rebate system," while the ...
FTC report: Pharmacy benefit managers profit at expense of ... - CNN
Jul 9, 2024 · Pharmacy benefit managers, which negotiate the terms for prescription drug access for hundreds of millions of Americans, are racking up profits while squeezing patients and independent...
FTC: Big 3 PBMs generated $7.3B from specialty generic markups
3 days ago · The FTC’s first interim report—which detailed the impacts of vertical integration and unfair contractual relationships—was more limited in scope, only analyzing a couple specialty generic ...
Healthcare Leaders Support FTC's Second Report on PBMs, While …
2 days ago · The new report is the latest development in a battle that has been brewing between the FTC and the PBMs. The agency released its first interim staff report on PBMs in July, which detailed how ...
New FTC Report Finds PBMs Increased Prices for Specialty Cancer, …
2 days ago · The new report comes months after the first interim staff report was released in July 2024, which found that PBMs had an outsized impact on the pharmaceutical industry and negatively impacted the accessibility and affordability of prescription drugs. Shortly after the release of the first interim report, the FTC announced their intention to sue the big 3 PBMs for their unfair negotiating ...
- Some results have been removed